Articles

Videos

Podcasts

Clinical

Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

FDA Approves Bevacizumab Biosimilar for Six Types of Cancer

The FDA accepted a supplemental New Drug Application for tucatinib to treat HER2 colorectal cancer, which could significantly improve outcomes for these patients.

FDA Grants Priority Review to Tucatinib With Trastuzumab to Treat HER2 Colorectal Cancer

Selpercatinib produced clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers.

FDA Approves Selpercatinib for Advanced, Metastatic Solid Tumors With RET Gene Fusion

Study indicates that a diet high in ultra-processed food is more likely to increase the risk of colorectal cancer in men than it is women. 

Ultra-Processed Foods Found to Increase Colorectal Cancer Risk in Men

Therapy shows positive clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients who have a KRASG12C mutation.

Mirati Releases Promising Adagrasib Results for Advanced Colorectal Cancer

Fruquintinib reduced the risk of death in patients with advanced metastatic colorectal cancer by 34% and led to longer overall survival than among those given placebo. 

Fruquintinib Meets Primary Endpoint of Overall Survival for Metastatic Colorectal Cancer

Processed meats and products high in added sugars and low in fiber contribute to weight gain and obesity, which is an established risk factor.

Results of New Harvard, Tufts Study Link Colorectal Cancer in Men to Ultra-Processed Foods

Andrew Barnell, MBA, CEO and co-founder of Geneoscopy, discusses his meeting at the White House on President Biden’s Cancer Moonshot initiative.

Expert Discusses White House Meeting to Address Increasing Colorectal Cancer Screenings, Health Equity

Scientists found that inhibiting certain immune system receptors could treat colon cancer and other diseases of the gastrointestinal tract.

New Therapeutic Targets Could Treat Colon Tumors, Inflammatory Bowel Disease

Gamma-delta T-cells undergo a biochemical change that leads them to spur the growth of tumors that previously restricted.

T-cells First Protect Against but then Promote Growth of Colorectal Cancer Tumors, Study Finds

® Colorectal Cancer Resource Center is a comprehensive resource for clinical news and expert insights on cancers that start 